IDH2 R140Q in MDS — enasidenib monotherapy active in MDS (NCT01915498, DiNardo et al. Blo...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH2-R140Q-MDS-LR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-LR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH2 R140Q |
| Disease | DIS-MDS-LR |
| ESCAT tier | IIA |
| Recommended combinations | enasidenib (off-label MDS) |
| Evidence summary | IDH2 R140Q in MDS — enasidenib monotherapy active in MDS (NCT01915498, DiNardo et al. Blood 2018). IDH-mut MDS often progresses to AML; IDH2i can delay transformation. Not yet on full FDA MDS label (off-label use NCCN-supported). |
Notes
ESCAT IIA. Off-label in MDS pending Ph3 readout. Frontline MDS-LR luspatercept / HMA; MDS-HR HMA ± venetoclax.
Used By
No reverse references found in the YAML corpus.